These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 20598769)

  • 21. Efficacy of bevacizumab-containing chemotherapy for non-squamous non-small cell lung cancer with bone metastases.
    Tokito T; Shukuya T; Akamatsu H; Taira T; Ono A; Kenmotsu H; Naito T; Murakami H; Takahashi T; Endo M; Yamamoto N
    Cancer Chemother Pharmacol; 2013 Jun; 71(6):1493-8. PubMed ID: 23532208
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation.
    Park SJ; Kim HT; Lee DH; Kim KP; Kim SW; Suh C; Lee JS
    Lung Cancer; 2012 Sep; 77(3):556-60. PubMed ID: 22677429
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical impact of amphiregulin expression in patients with epidermal growth factor receptor (EGFR) wild-type nonsmall cell lung cancer treated with EGFR-tyrosine kinase inhibitors.
    Chang MH; Ahn HK; Lee J; Jung CK; Choi YL; Park YH; Ahn JS; Park K; Ahn MJ
    Cancer; 2011 Jan; 117(1):143-51. PubMed ID: 20803614
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Retreatment with erlotinib: Regain of TKI sensitivity following a drug holiday for patients with NSCLC who initially responded to EGFR-TKI treatment.
    Becker A; Crombag L; Heideman DA; Thunnissen FB; van Wijk AW; Postmus PE; Smit EF
    Eur J Cancer; 2011 Nov; 47(17):2603-6. PubMed ID: 21784628
    [TBL] [Abstract][Full Text] [Related]  

  • 25. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.
    Herbst RS; Prager D; Hermann R; Fehrenbacher L; Johnson BE; Sandler A; Kris MG; Tran HT; Klein P; Li X; Ramies D; Johnson DH; Miller VA;
    J Clin Oncol; 2005 Sep; 23(25):5892-9. PubMed ID: 16043829
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer.
    Delea T; Langer C; McKiernan J; Liss M; Edelsberg J; Brandman J; Sung J; Raut M; Oster G
    Oncology; 2004; 67(5-6):390-6. PubMed ID: 15713995
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Skeletal metastases in non-small cell lung cancer: a retrospective study.
    Tsuya A; Kurata T; Tamura K; Fukuoka M
    Lung Cancer; 2007 Aug; 57(2):229-32. PubMed ID: 17451841
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prolonged control of bone metastases in non-small-cell lung cancer patients treated with gefitinib.
    Zampa G; Moscato M; Brannigan BW; Morabito A; Bell DW; Normanno N
    Lung Cancer; 2008 Jun; 60(3):452-4. PubMed ID: 18079016
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bone metastasis, skeletal-related events, and mortality in lung cancer patients: a Danish population-based cohort study.
    Cetin K; Christiansen CF; Jacobsen JB; Nørgaard M; Sørensen HT
    Lung Cancer; 2014 Nov; 86(2):247-54. PubMed ID: 25240518
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of EGFR SNPs in survival of advanced lung adenocarcinoma patients treated with Gefitinib.
    Zhang L; Yuan X; Chen Y; Du XJ; Yu S; Yang M
    Gene; 2013 Mar; 517(1):60-4. PubMed ID: 23313300
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Retrospective study of the effect of skeletal complications on total medical care costs in patients with bone metastases of breast cancer seen in typical clinical practice.
    Delea T; McKiernan J; Brandman J; Edelsberg J; Sung J; Raut M; Oster G
    J Support Oncol; 2006; 4(7):341-7. PubMed ID: 16892696
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Economic analysis: randomized placebo-controlled clinical trial of erlotinib in advanced non-small cell lung cancer.
    Bradbury PA; Tu D; Seymour L; Isogai PK; Zhu L; Ng R; Mittmann N; Tsao MS; Evans WK; Shepherd FA; Leighl NB;
    J Natl Cancer Inst; 2010 Mar; 102(5):298-306. PubMed ID: 20160168
    [TBL] [Abstract][Full Text] [Related]  

  • 33. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.
    Sequist LV; Martins RG; Spigel D; Grunberg SM; Spira A; Jänne PA; Joshi VA; McCollum D; Evans TL; Muzikansky A; Kuhlmann GL; Han M; Goldberg JS; Settleman J; Iafrate AJ; Engelman JA; Haber DA; Johnson BE; Lynch TJ
    J Clin Oncol; 2008 May; 26(15):2442-9. PubMed ID: 18458038
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer.
    Kobayashi T; Koizumi T; Agatsuma T; Yasuo M; Tsushima K; Kubo K; Eda S; Kuraishi H; Koyama S; Hachiya T; Ohura N
    Cancer Chemother Pharmacol; 2012 May; 69(5):1241-6. PubMed ID: 22278730
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epidemiology and treatment costs of bone metastases from lung cancer: a French prospective, observational, multicenter study (GFPC 0601).
    Decroisette C; Monnet I; Berard H; Quere G; Le Caer H; Bota S; Audigier-Valette C; Geriniere L; Vernejoux JM; Chouaid C;
    J Thorac Oncol; 2011 Mar; 6(3):576-82. PubMed ID: 21270669
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictors of gefitinib outcomes in advanced non-small cell lung cancer (NSCLC): study of a comprehensive panel of molecular markers.
    Tiseo M; Rossi G; Capelletti M; Sartori G; Spiritelli E; Marchioni A; Bozzetti C; De Palma G; Lagrasta C; Campanini N; Camisa R; Boni L; Franciosi V; Rindi G; Ardizzoni A
    Lung Cancer; 2010 Mar; 67(3):355-60. PubMed ID: 19473722
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Non-small cell lung cancer-smokers or non-smokers, does it matter?
    Barlési F; Nanni-Metellus I; Breen D; Fina F; Astoul P; Martin PM
    Lung Cancer; 2009 Mar; 63(3):430-2. PubMed ID: 18789554
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Skeletal related events in patients with bone metastasis arising from non-small cell lung cancer.
    da Silva GT; Bergmann A; Thuler LCS
    Support Care Cancer; 2016 Feb; 24(2):731-736. PubMed ID: 26143039
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prediction of skeletal-related events in patients with non-small cell lung cancer.
    Aiba H; Kimura T; Yamagami T; Watanabe N; Sakurai H; Kimura H; Shimozaki S; Yamada S; Otsuka T
    Support Care Cancer; 2016 Aug; 24(8):3361-7. PubMed ID: 26980332
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The incidence and clinical impact of bone metastases in non-small cell lung cancer.
    Kuchuk M; Kuchuk I; Sabri E; Hutton B; Clemons M; Wheatley-Price P
    Lung Cancer; 2015 Aug; 89(2):197-202. PubMed ID: 26003503
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.